LifeStance Health Group earnings release, August 6, 2026

LifeStance Health Group, Inc. (LFST) · Form 8-K, Item 2.02 · Filed · SEC filing

Investor Relations Contact

Monica Prokocki

VP of Finance & Investor Relations

602-767-2100 investor.relations@lifestance.com

LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook

Announces $100 Million Share Repurchase Program

SCOTTSDALE, Ariz. – August 6, 2026 – LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation’s largest providers of outpatient mental healthcare, today announced financial results for the second quarter ended June 30, 2026.

(All results compared to prior-year comparative period, unless otherwise noted)

Q2 2026 Highlights and FY 2026 Outlook

• Revenue of $435.4 million increased 26% compared to revenue of $345.3 million

• Clinician base increased 11% to 8,542 clinicians, a sequential net increase of 193 in the second quarter

• Second quarter visit volumes increased 19% to 2.6 million

• Net income of $23.6 million compared to net loss of $3.8 million

• Adjusted EBITDA of $66.0 million compared to Adjusted EBITDA of $34.0 million

• Net cash provided by operations of $99.9 million in the second quarter

• Free Cash Flow generation of $87.9 million in the second quarter

• For full year 2026, raising revenue expectations to $1.685 billion to $1.725 billion, Center Margin expectations to $570 million to $594 million, and Adjusted EBITDA of $215 million to $235 million

“This was an outstanding second quarter and first half of 2026 for LifeStance, as we delivered quarterly revenue growth of 26%, positive net income of $24 million, and Adjusted EBITDA margins of 15%.” said Dave Bourdon, CEO of LifeStance. “This momentum underscores the substantial growth opportunity ahead as we extend our reach into new geographies, broaden our specialty capabilities, and strengthen our differentiation through clinical excellence and measurable patient outcomes.”

NM - not meaningful

(All results compared to prior-year period, unless otherwise noted)

• Revenue grew 26% to $435.4 million. Revenue growth in the second quarter was driven primarily by higher visit volumes from net clinician growth, improved clinician productivity, and higher total revenue per visit.

• i ncome from operations was $30.7 million and net income was $23.6 million.

• Center Margin grew 41% to $153.0 million, or 35.2% of total revenue.

• Adjusted EBITDA increased 94% to $66.0 million, or 15.2% of total revenue. Adjusted EBITDA as a percentage of revenue increased in the second quarter as a result of higher total revenue per visit, lower center costs as a percentage of revenue, and improved operating leverage from revenue growing faster than general and administrative expenses.

Balance Sheet, Cash Flow, and Capital Allocation

For the six months ended June 30, 2026, LifeStance generated $133.0 million of cash flow from operations, including $99.9 million during the second quarter of 2026. The Company ended the second quarter with cash and cash equivalents of $225.9 million and net long-term debt of $259.0 million.

2026 Guidance

LifeStance is providing the following outlook for 2026:

• The Company is raising full year revenue to $1.685 billion to $1.725 billion, Center Margin to $570 million to $594 million, and Adjusted EBITDA to $215 million to $235 million.

• For the third quarter of 2026, the Company expects total revenue of $420 million to $440 million, Center Margin of $140 million to $152 million, and Adjusted EBITDA of $49 million to $59 million.

Share Repurchase Program

The Company's Board of Directors has approved a share repurchase program authorizing the repurchase of up to $100 million of the Company's outstanding common stock, which replaces the Company's prior $100 million repurchase program approved by the Board of Directors of the Company on February 24, 2026. Repurchases may be made from time to time at the Company's discretion in the open market or through privately negotiated transactions, including accelerated share repurchase programs, subject to market conditions and other relevant factors.

Conference Call, Webcast Information, and Presentations

LifeStance will hold a conference call today, August 6, 2026 at 8:30 a.m. Eastern Time to discuss the second quarter 2026 results. Investors who wish to participate in the call should dial 1-800-715-9871, domestically, or 1-646-307-1963, internationally, approximately 10 minutes before the call begins and provide conference ID number 6776851 or ask to be joined into the LifeStance call. A real-time audio webcast can be accessed via the Events and Presentations section of the LifeStance Investor Relations website (https://investor.lifestance.com), where related materials will be posted prior to the conference call.

About LifeStance Health Group, Inc.

Founded in 2017, LifeStance (Nasdaq: LFST) is reimagining mental health. We are one of the nation’s largest providers of virtual and in-person outpatient mental healthcare for children, adolescents and adults experiencing a variety of mental health conditions. Our mission is to help people lead healthier, more fulfilling lives by improving access to trusted, affordable, and personalized mental healthcare. LifeStance and its supported practices employ over 8,500 psychiatrists, advanced practice nurses, psychologists and therapists and operates across 33 states and more than 550 centers. To learn more, please visit www.LifeStance.com.

We routinely post information that may be important to investors on the “Investor Relations” section of our website at investor.lifestance.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Financial statements

Income Statement (in millions)

Q2 2026Q2 2025Y/Y
(in millions)Total revenue435.4345.326.0%
(in millions)Income (loss) from operations30.7-3
(in millions)Center Margin153108.441.0%
(in millions)Net income (loss)23.6-3.8
(in millions)Adjusted EBITDA663494.0%
As % of Total revenue:Income (loss) from operations7%)
As % of Total revenue:Center Margin35.231.4%
As % of Total revenue:Net income (loss)5.4%)
As % of Total revenue:Adjusted EBITDA15.29.8%

Income Statement

Three Months Ended June 30, — (In thousands, except per share amounts)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
TOTAL REVENUE435,354345,311838,830678,281
OPERATING EXPENSESCenter costs, excluding depreciation and amortization shown separately below282,313236,880549,857460,059
OPERATING EXPENSESGeneral and administrative expenses108,13997,375208,469191,806
OPERATING EXPENSESDepreciation and amortization14,24914,00627,56727,762
OPERATING EXPENSESTotal operating expenses404,701348,261785,893679,627
OPERATING EXPENSESINCOME (LOSS) FROM OPERATIONS30,653-2,95052,937-1,346
OTHER EXPENSELoss on remeasurement of contingent consideration-26-31
OTHER EXPENSETransaction costs-445-989
OTHER EXPENSEInterest expense, net-2,632-2,900-4,425-5,973
OTHER EXPENSEOther expense-93-92-275-93
OTHER EXPENSETotal other expense-3,196-2,992-5,720-6,066
OTHER EXPENSEINCOME (LOSS) BEFORE INCOME TAXES27,457-5,94247,217-7,412
OTHER EXPENSEINCOME TAX (PROVISION) BENEFIT-3,8452,151-9,3624,330
OTHER EXPENSENET INCOME (LOSS)23,612-3,79137,855-3,082
EARNINGS (LOSS) PER SHAREBasic0.06-0.010.1-0.01
EARNINGS (LOSS) PER SHAREDiluted0.06-0.010.1-0.01
Weighted-average shares outstandingBasic383,516386,733385,379385,015
Weighted-average shares outstandingDiluted387,299386,733391,181385,015
Weighted-average shares outstandingNET INCOME (LOSS)23,612-3,79137,855-3,082
OTHER COMPREHENSIVE LOSSUnrealized losses on cash flow hedge, net of tax-267-584
OTHER COMPREHENSIVE LOSSCOMPREHENSIVE INCOME (LOSS)23,612-4,05837,855-3,666

Income Statement

Three Months Ended June 30, — TO ADJUSTED EBITDA (in thousands)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Net income (loss)23,612-3,79137,855-3,082
Adjusted for:Interest expense, net2,6322,9004,4255,973
Adjusted for:Depreciation and amortization14,24914,00627,56727,762
Adjusted for:Income tax provision (benefit)3,845-2,1519,362-4,330
Adjusted for:Loss on remeasurement of contingent consideration2631
Adjusted for:Stock-based compensation expense19,74821,11634,94939,700
Adjusted for:Loss on disposal of assets939227593
Adjusted for:Transaction costs (1)445989
Adjusted for:Executive transition costs534719
Adjusted for:Litigation costs (2)69953-1281,158
Adjusted for:Strategic initiatives (3)911997
Adjusted for:Real estate optimization and restructuring charges (4)-11-52-11-97
Adjusted for:Amortization of cloud-based software implementation costs (5)423398841755
Adjusted for:Adjusted EBITDA66,04234,005117,15268,651

Balance Sheet

June 30, 2026 — (In thousands, except for par value)

June 30, 2026December 31, 2025
CURRENT ASSETSCash and cash equivalents225,943248,642
CURRENT ASSETSPatient accounts receivable, net110,96095,710
CURRENT ASSETSPrepaid expenses and other current assets41,06371,848
CURRENT ASSETSTotal current assets377,966416,200
NONCURRENT ASSETSProperty and equipment, net164,696161,583
NONCURRENT ASSETSRight-of-use assets157,007149,720
NONCURRENT ASSETSIntangible assets, net172,805177,665
NONCURRENT ASSETSGoodwill1,304,5561,293,346
NONCURRENT ASSETSOther noncurrent assets4,4665,419
NONCURRENT ASSETSTotal noncurrent assets1,803,5301,787,733
NONCURRENT ASSETSTotal assets2,181,4962,203,933
CURRENT LIABILITIESAccounts payable11,0536,122
CURRENT LIABILITIESAccrued payroll expenses149,320143,327
CURRENT LIABILITIESOther accrued expenses49,55142,187
CURRENT LIABILITIESOperating lease liabilities, current46,50045,544
CURRENT LIABILITIESOther current liabilities18,32914,782
CURRENT LIABILITIESTotal current liabilities274,753251,962
NONCURRENT LIABILITIESLong-term debt, net258,991265,927
NONCURRENT LIABILITIESOperating lease liabilities, noncurrent154,159148,553
NONCURRENT LIABILITIESDeferred tax liability, net16,40816,408
NONCURRENT LIABILITIESOther noncurrent liabilities3768
NONCURRENT LIABILITIESTotal noncurrent liabilities429,595430,956
NONCURRENT LIABILITIESTotal liabilities704,348682,918
STOCKHOLDERS’ EQUITYCommon stock – par value $0.01 per share; 800,000 shares authorized as of June 30, 2026 and December 31, 2025; 382,022 and 388,318 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively3,8203,883
STOCKHOLDERS’ EQUITYAdditional paid-in capital2,244,0992,325,758
STOCKHOLDERS’ EQUITYAccumulated deficit-770,771-808,626
STOCKHOLDERS’ EQUITYTotal stockholders' equity1,477,1481,521,015
STOCKHOLDERS’ EQUITYTotal liabilities and stockholders’ equity2,181,4962,203,933
Full release

Forward-Looking Statements... (truncated)nd management's related assumptions; business plans and objectives; our share repurchase authorization and repurchases thereunder; and other statements contained in this press release that are not historical facts. When used in this press release and on the related teleconference, words such as “may,” “will,” “should,” “could,” “intend,” “potential,” “continue,” “anticipate,” “believe,” “estimate,” “expect,” “plan,” “target,” “predict,” “project,” “seek” and similar expressions as they relate to us are intended to identify forward-looking statements. They involve a number of risks and uncertainties that may cause actual events and results to differ materially from such forward-looking statements. These risks and uncertainties include, but are not limited to: if reimbursement rates paid by third-party payors are reduced or if third-party payors otherwise restrain our ability to obtain or deliver care to patients, our business could be materially harmed; we may not grow at the rates we historically have achieved or at all, even if our key metrics may imply future growth, including if we are unable to successfully execute on our growth initiatives and business strategies; if we fail to manage our growth effectively, our expenses could increase more than expected, our revenue may not increase proportionally or at all, and we may be unable to execute on our business strategy; our ability to recruit new clinicians and retain existing clinicians; we conduct business in a heavily regulated industry and if we fail to comply with these laws and government regulations, we could incur penalties or be required to make significant changes to our operations or experience adverse publicity, which could have a material adverse effect on our business, results of operations and financial condition; we are dependent on our relationships with supported practices, which we do not own, to provide healthcare services, and our business would be harmed if those relationships were disrupted or if our arrangements with these entities became subject to legal challenges; we operate in a competitive industry, and if we are not able to compete effectively, our business and financial performance would be harmed; the impact on us of healthcare reform legislation and other changes in the healthcare industry and in healthcare spending is currently unknown, but may harm our business; if our or our vendors’ security measures fail or are breached and unauthorized access to our employees’, patients’ or partners’ data is obtained, our systems may be perceived as insecure, we may incur significant liabilities, including through private litigation or regulatory action, our reputation may be harmed, and we could lose patients and partners; our business depends on our ability to effectively invest in, implement improvements to and properly maintain the uninterrupted operation and data integrity of our information technology and other business systems; our existing indebtedness could adversely affect our business and growth prospects; and other risks and uncertainties set forth under “Risk Factors” included in the reports we have filed or will file with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent filings made with the Securities and Exchange Commission. LifeStance does not undertake to update any forward-looking statements made in this press release to reflect any change in management's expectations or any change in the assumptions or circumstances on which such statements are based, except as otherwise required by law.

Non-GAAP Financial Information

This press release contains certain non-GAAP financial measures, including Center Margin, Adjusted EBITDA, and Adjusted EBITDA margin. Tables showing the reconciliation of these non-GAAP financial measures to the comparable GAAP measures are included at the end of this release. Management believes these non-GAAP financial measures are useful in evaluating the Company’s operating performance, and may be helpful to securities analysts, institutional investors and other interested parties in understanding the Company’s operating performance and prospects. This press release also refers to Free Cash Flow, which is calculated as net cash provided by operating activities less purchases of property and equipment. Management believes Free Cash Flow is a useful indicator of liquidity that provides information to management and investors about the amount of cash generated from our operations that, after investments in property and equipment, can be used for future growth. These non-GAAP financial measures, as calculated, may not be comparable to companies in other industries or within the same industry with similarly titled measures of performance. Therefore, the Company’s non-GAAP financial measures should be considered in addition to, not as a substitute for, or in isolation from, measures prepared in accordance with GAAP, such as net income (loss) or income (loss) from operations.

Center Margin and Adjusted EBITDA anticipated for the third quarter of 2026 and full year 2026 are calculated in a manner consistent with the historical presentation of these measures at the end of this release. Reconciliation for the forward-looking third quarter of 2026 and full year 2026 Center Margin, Adjusted EBITDA guidance and Free Cash Flow is not being provided, as LifeStance does not currently have sufficient data to accurately estimate the variables and individual adjustments for such reconciliation. As such, LifeStance management cannot estimate on a forward-looking basis without unreasonable effort the impact these variables and individual adjustments will have on its reported results.... (truncated)results.

# # # #

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · LifeStance Health Group earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.